A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.

@article{Greco1996ACT,
  title={A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.},
  author={Donato Greco and Stefania Salmaso and Paola Mastrantonio and Marina Giuliano and Alberto Eugenio Tozzi and Alessandra Anemona and Marta Luisa Ciofi Degli Atti and Anna Giammanco and Pietro Panei and William C Blackwelder and David L. Klein and Steven G. F. Wassilak},
  journal={The New England journal of medicine},
  year={1996},
  volume={334 6},
  pages={
          341-8
        }
}
BACKGROUND Concern about both safety and efficacy has made the use of whole-cell pertussis vaccines controversial. In some European countries, including Italy, the rate of vaccination against pertussis is low. METHODS We conducted a double-blind trial in Italy in which infants were randomly assigned to vaccination at two, four, and six months of age with an acellular pertussis vaccine together with diphtheria and tetanus toxoids (DTP); a DTP vaccine containing whole-cell pertussis… 

Tables from this paper

Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults
TLDR
In this first clinical study, PTgen-based BioNet's aP and TdaP vaccines showed a similar tolerability and safety profile to Adacel® and elicited significantly higher immune responses to PT and FHA.
A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.
TLDR
The five-component acellular pertussis vaccine evaluated can be recommended for general use, since it has a favorable safety profile and confers sustained protection against pertussi.
Efficacy of a two-component acellular pertussis vaccine in infants.
TLDR
Three doses of the two-component acellular pertussis vaccine protected infants against pertussi disease during the period before the recommended booster vaccination, and efficacy was high and similar to that of a licensed German diphtheria-tetanus toxoids-whole cell pertussIS vaccine.
Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents.
TLDR
Booster immunization of adolescents with an acellular vaccine containing reduced quantities of pertussis antigens in addition to diphtheria and tetanus toxoids induces good responses in both arms of the immune system without an increase in adverse reactions.
A Critical Evaluation of Whole Cell Pertussis Vaccines on their Composition and Efficacy in Comparison to Acellular Pertussis Vaccines
TLDR
The acellular pertussis vaccine's failure to deliver durable infection to children had also led to the 2010 California epidemic and the duration of protection after immunization by wP vaccine is more as compared to aP vaccine and the average longest protection lasts for about 10-12 years.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 38 REFERENCES
A placebo-controlled trial of a pertussis-toxoid vaccine.
TLDR
A pharmacologically inert, acellular pertussis-toxoid vaccine that is easily standardized is safe and confers substantial protection against pertussi.
A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.
TLDR
The five-component acellular pertussis vaccine evaluated can be recommended for general use, since it has a favorable safety profile and confers sustained protection against pertussi.
Comparison of 13 acellular pertussis vaccines: overview and serologic response.
TLDR
It is clear that DTaP vaccines can stimulate immune responses that exceed those of licensed whole-cell vaccine with respect to the measured antibodies.
Comparison of 13 acellular pertussis vaccines: adverse reactions.
TLDR
Although there were differences among the acellular vaccines, none was consistently the most or least reactogenic; all were associated with substantially fewer and less severe adverse reactions than a standard commercial whole-cell vaccine.
Primary immunization of infants with an acellular pertussis vaccine in a double-blind randomized clinical trial.
The rate of adverse reactions and the immunogenicity of a two-component acellular pertussis vaccine as compared with a plain whole-cell vaccine and a placebo were evaluated for primary immunization
Protective efficacy of the Takeda acellular pertussis vaccine combined with diphtheria and tetanus toxoids following household exposure of Japanese children.
TLDR
It is concluded that prior immunization with this four-component pertussis vaccine combined with diphtheria and tetanus toxoids is highly efficacious in preventing pertussi.
Efficacy of acellular pertussis vaccine in early childhood after household exposure.
TLDR
Under conditions of intense household exposure, primary vaccination with acellular vaccine protected against pertussis until at least the time recommended for booster vaccination.
Acellular pertussis vaccines--a solution to the pertussis problem?
  • K. Edwards
  • Biology, Medicine
    The Journal of infectious diseases
  • 1993
TLDR
There is reason to hope that within the next several years the information derived from ongoing and planned studies will support the general use of component acellular pertussis vaccines for the routine immunization of adults and children alike.
Differences in antibody response to whole-cell pertussis vaccines.
TLDR
Evaluation of other comparative data sets provided further support for the conclusion that the two commercially available WCVs consistently differed in their ability to induce antibody to pertussis toxin.
...
1
2
3
4
...